STOCK TITAN

Evolus to Report First Quarter 2021 Results and Provide Business Update

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Evolus, a performance beauty company, will report its first quarter 2021 financial results on May 12, 2021, after U.S. market close. A conference call will follow at 4:30 p.m. ET, providing a business update and a Q&A session. Domestic callers can access the call at (866) 916-2317, while international callers should use (703) 925-2662, with conference ID 7749489. A replay will be available until May 19, 2021. The event can also be streamed live via the Evolus Investor Relations website.

Positive
  • None.
Negative
  • None.

NEWPORT BEACH, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, announced today that it will report its first quarter 2021 financial results and provide a business update on Wednesday, May 12, 2021, after the close of the U.S. financial markets.

Management will host a conference call and live webcast to discuss Evolus’ financial results at 4:30 p.m. ET that same day. A question and answer session will follow management remarks.

The dial-in numbers for the conference call are (866) 916-2317 for domestic callers and (703) 925-2662 for international callers. The conference ID is 7749489.

A replay of the call will be available following its completion through May 19, 2021. To access the replay, dial (855) 859-2056 for domestic callers and (404) 537-3406 for international callers and use the replay conference ID 7749489.

A live audio webcast of the call will be available on the Investor Relations page of the Evolus, Inc. website, https://investors.evolus.com. A replay of the webcast will be archived on Evolus' website for 30 days following the completion of the call.

About Evolus, Inc.

Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. In 2019, the U.S. Food and Drug Administration approved Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Jeuveau® is powered by Evolus' unique technology platform and is designed to transform the aesthetic market by eliminating the friction points existing for customers today. Visit us at: http://www.evolus.com.

Jeuveau® is a registered trademark of Evolus, Inc.

Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.

Investor Contact
The Ruth Group
Christine Petraglia
Senior Vice President
Tel: 917-633-8980
Email: cpetraglia@theruthgroup.com 

 


FAQ

When will Evolus report its Q1 2021 financial results?

Evolus will report its first quarter 2021 financial results on May 12, 2021, after the U.S. market closes.

What time is the Evolus conference call on May 12, 2021?

The Evolus conference call is scheduled for 4:30 p.m. ET on May 12, 2021.

How can I access the Evolus conference call?

You can access the Evolus conference call by dialing (866) 916-2317 for domestic calls or (703) 925-2662 for international calls using conference ID 7749489.

Is there a replay available for the Evolus conference call?

Yes, a replay of the Evolus conference call will be available until May 19, 2021.

Where can I find the live webcast of the Evolus conference call?

The live webcast of the Evolus conference call can be found on the Investor Relations page of the Evolus website.

Evolus, Inc.

NASDAQ:EOLS

EOLS Rankings

EOLS Latest News

EOLS Stock Data

798.48M
50.17M
12.31%
80.2%
8.59%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
NEWPORT BEACH